SENTARA COMMUNITY PLAN (MEDICAID)

MEDICAL PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

<u>Directions:</u> The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; <u>fax to 1-844-305-2331</u>. No additional phone calls will be necessary if all information (<u>including phone and fax #s</u>) on this form is correct. <u>If information provided is not complete</u>, correct, or legible, authorization can be delayed.

<u>Drug Requested</u>: Cosentyx[®] (secukinumab) IV (J3247) (Medical)

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.				
Member Name:				
Member Sentara #:	Date of Birth:			
Prescriber Name:				
Prescriber Signature:	Date:			
Office Contact Name:				
Phone Number:	Fax Number:			
NPI #:				
DRUG INFORMATION: Authorization m	nay be delayed if incomplete.			
Drug Name/Form/Strength:				
Dosing Schedule:	Length of Therapy:			
Diagnosis:	ICD Code, if applicable:			
Weight (if applicable):	Date weight obtained:			
Standard Review. In checking this box, the timeframe does not jeopardize the life or health of the member or the member's ability to regain maximum function and would not subject the member to severe pain.				
Cosentyx 125 mg/5mL solution; 1ml vial and 5ml vial = 125 billable units				
· ·	r <u>both</u> Medical and Pharmacy benefits lect correct PA form)			
DIACNOSIS	Pagammandad Daga			

DIAGNOSIS Recommended Dose Active Ankylosing Spondylitis Active Non-Radiographic Axial Spondyloarthritis (nr-axSpA) − with objective signs of inflammation Active Psoriatic Arthritis Recommended Dose With a loading dosage: 6 mg/kg given at Week 0 as a loading dose, followed by 1.75 mg/kg every 4 weeks thereafter (max. maintenance dose 300 mg per infusion) Without a loading dosage: 1.75 mg/kg every 4 weeks (max. maintenance dose 300 mg per infusion)

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

□ Diagnosis: Active Ankylosing Spondylitis				
	Member is 18 years of age or older			
	Member has a diagnosis of active ankylosing spondylitis			
	Trial and failure of TWO (2) of the preferred drugs below (check each tried):			
	☐ Humira [®]	□ Enbrel [®]	□ Infliximab	
□ Diagnosis: Non-Radiographic Axial Spondyloarthritis				
	Member is 18 years of age or older			
	Member has a diagnosis of Active Non-radiographic Axial Spondylarthritis (nr-axSpA) with objective signs of inflammation			
□ Diagnosis: Active Psoriatic Arthritis				
	Member is 2 years of age or older			
	Member has a diagnosis of active psoriatic arthritis			
	Trial and failure of <u>TWO</u> (2) of the preferred drugs below (check each tried):			
	☐ Humira [®]	□ Enbrel [®]	□ Infliximab	
Medication being provided by: Please check applicable box below.				
□ Location/site of drug administration:				
NPI or DEA # of administering location:				
	<u>OR</u>			

For urgent reviews: Practitioner should call Sentara Health Pre-Authorization Department if they believe a standard review would subject the member to adverse health consequences. Sentara Health's definition of urgent is a lack of treatment that could seriously jeopardize the life or health of the member or the member's ability to regain maximum function.

□ Specialty Pharmacy – PropriumRx

^{*}Use of samples to initiate therapy does not meet step-edit/preauthorization criteria.*

^{*}Previous therapies will be verified through pharmacy paid claims or submitted chart notes.*